Lucid Psycheceuticals (Lucid) has two active pipelines under development
Lucid's team has shortlisted Lucid-201, a known molecule with clinical proof of efficacy in major depressive disorder (MDD) and related psychiatric conditions. Lucid has developed a proprietary synthetic protocol, and is continuing to develop a proprietary position on its manufacturing and a unique drug formulation. Simultaneously, Lucid is conducting investigations to complete IND-enabling studies. Lucid has a research contract with University Health Network (Toronto, Canada) until 2023 for various animal model studies and other related activities. Lucid intends to bring these assets into clinical trials initially in Canada followed by USA, and subsequently targeting global markets. These assets are also going to pay an important role in the development of drugs for neurodegenerative disorders under Lucid umbrella.
Lucid completed the acquisition of exclusive world-wide license to new chemical entities (NCEs), associated patents and preclinical efficacy data from University Health Network (UHN, Toronto, Canada) in May 2021. Lucid is proud to have acquired this technology and partner with UHN for its further development. This technology has over 10 years of R&D and unique technology behind it, that provides neuroprotection in the central nervous system. This forms the basis for the neurodegenerative disorders pipeline currently, and the first therapeutic area is multiple sclerosis (MS). Currently, the lead compound is undergoing scale-up processing, and IND-enabling studies.